Inventor · disambiguated record
Giovanni Abbadessa
Also filed as: ABBADESSA GIOVANNI
1 granted patent·10 pending applications·2 citations·filing 2011–2025
19Inventor score
Top patents by PatentIndex Score
11 records- 0169US2024245792A1Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumabSYNTHORX INC·Filed 2023·Application pending·0 cites
- 0269US2024226309A1Head and neck cancer combination therapy comprising an il-2 conjugate and cetuximabSYNTHORX INC·Filed 2023·Application pending·0 cites
- 0364US8580764B2Combinational compositions and methods for treatment of cancerABBADESSA GIOVANNI·Filed 2011·Granted Nov 12, 2013·2 cites·17 claims
- 0464US2025064935A1Natural killer cells and cd123 nk cell engager combination therapySANOFI SA·Filed 2024·Application pending·0 cites
- 0561US2025019441A1Treatment of cancer with anti-ilt2 antibodiesBIOND BIOLOGICS LTD·Filed 2024·Application pending·0 cites
- 0659US2023381335A1Lung cancer combination therapy with il-2 conjugates and an anti-pd-1 antibody or antigen-binding fragment thereofSYNTHORX INC·Filed 2023·Application pending·0 cites
- 0759US2025195653A1Multifunctional natural killer (nk) cell engager combination therapy for treating hematological neoplastic disordersSANOFI SA·Filed 2024·Application pending·0 cites
- 0858US2025302950A1Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumabSYNTHORX INC·Filed 2022·Application pending·0 cites
- 0949US2025376537A1Methods of treating cancer using trispecific binding proteins targeting her2-expressing tumorsSANOFI SA·Filed 2025·Application pending·0 cites
- 1048US2022016252A1Immuno oncology combination therapy with il-2 conjugates and anti-egfr antibodiesSYNTHORX INC·Filed 2021·Application pending·0 cites
- 1133US2011301194A1Method for Determining Treatment EfficacyCHAN THOMAS C K·Filed 2011·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →